Other Consolidated Financial Statement Detail (Tables)

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental cash flow information

Supplemental disclosure of cash flow information is summarized as follows:

	For the Years Ended December 31,
(In millions)	2024		2023		2022
Cash paid during the year for:
Interest	$	245.4	$	252.2	$	262.5
Income taxes	355.1		740.7		932.9

Other income (expense), net

Components of other (income) expense, net, are summarized as follows:

	For the Years Ended December 31,
(In millions)	2024		2023		2022
Interest income	$	(67.6)	$	(276.5)	$	(89.3)
Interest expense	250.3		246.9		246.6
(Gains) losses on investments, net	100.4		291.2		277.3
Foreign exchange (gains) losses, net	30.9		50.4		35.5
Gain on sale of equity interest in Samsung Bioepis(1)	—		—		(1,505.4)
Litigation settlement agreement and settlement fees	—		—		917.0
Other, net	29.6		3.5		10.1
Total other (income) expense, net	$	343.6	$	315.5	$	(108.2)

(1) Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 3, Dispositions, to these consolidated financial statements.

Gain (loss) on investments

The following table summarizes our (gains) losses on investments, net that relates to our equity securities held during the following periods:

	For the Years Ended December 31,
(In millions)	2024		2023		2022
Net (gains) losses recognized on equity securities	$	100.4	$	275.2	$	264.7
Less: Net (gains) losses realized on equity securities	(2.0)		5.2		—
Net unrealized (gains) losses recognized on equity securities	$	102.4	$	270.0	$	264.7

Accrued expense and other

Accrued expense and other consists of the following:

	As of December 31,
(In millions)	2024		2023
Revenue-related reserves for discounts and allowances	$	937.5	$	926.5
Employee compensation and benefits	375.8		335.1
Collaboration expense	309.0		214.6
Royalties and licensing fees	190.2		191.5
Current portion of contingent consideration obligations	291.2		—
Other	704.0		955.9
Total accrued expense and other	$	2,807.7	$	2,623.6